The Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program

The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 26 April
2013 resolved - for the purpose of ensuring that the company can fulfil its
commitments under the long-term incentive program resolved by the annual general
meeting - on a directed share issue of no more than 754,912 redeemable and
convertible class C shares.

The general meeting also resolved to authorize the board of directors to resolve
on the repurchase of all issued class C shares by an offer directed to all
holders of class C shares. Repurchase under this authorization may be made on
one or several occasions until the annual general meeting in 2014 and at a price
to no less than 100 per cent and no more than 105 per cent of the quotient value
of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorization for
the said purpose by repurchasing of all issued class C shares against payment of
100 per cent of the quotient value of the share, corresponding to approximately
SEK 0.55 per share. Repurchase of the class C shares may be effected during the
period 19 September - 29 September 2013.

The company currently holds 4,408,260 own class C shares. Subsequently to the
effected repurchase of class C shares above, the number of own class C shares
will amount to 5,163,172.

The class C shares will, following the repurchase, be converted to common shares
in the number that is required to ensure delivery under the incentive program.

---


About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com


For more information - not for publication

Media relations                      Investor relations

Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
                                     Investor Relations

T: +46 70 410 71 80                  T: +46 8 697 20 00

oskar.bosson@sobi.com                jorgen.winroth@sobi.com




The information was released for public distribution on 13 September 2013 at
08:00 CET.